latent transforming growth factor beta binding protein 3Genealiases: DASS · GPHYSD3 · LTBP-3 · LTBP2 · STHAG6 · pp6425
Q-omics provides the consensus-scored LTBP3 profile across patient tissues and cancer cell-line models. LTBP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LTBP3 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, LTBP3 protein abundance shows 20,560 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where LTBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LTBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LTBP3 survival associations across molecular data types. LTBP3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LTBP3 RNA expression–survival associations across cancer types. High LTBP3 expression shows unfavorable associations in LGG, COAD and CESC, but favorable associations in HNSC, SKCM and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LTBP3 RNA expression.
This table summarizes LTBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LTBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LTBP3 shows lower tumor expression in BLCA, KICH, UCEC and BRCA and higher tumor expression in CHOL and LIHC. The BLCA box plot shows higher LTBP3 RNA expression in normal versus tumor tissue (log2 FC = −1.346, t-test p = .001).
This table shows molecular features associated with LTBP3 in patient tissues and cancer cell lines. In patient samples, LTBP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LTBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
